Antonio Gasbarrini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5377448/publications.pdf

Version: 2024-02-01

387 papers

15,221 citations

59 h-index 100 g-index

389 all docs 389 docs citations

times ranked

389

20157 citing authors

#	Article	IF	CITATIONS
1	European consensus conference on faecal microbiota transplantation in clinical practice. Gut, 2017, 66, 569-580.	12.1	793
2	Antibiotics as deep modulators of gut microbiota: between good and evil. Gut, 2016, 65, 1906-1915.	12.1	463
3	Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. Hepatology, 2019, 69, 107-120.	7.3	433
4	Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development. Journal of Hepatology, 2009, 51, 682-689.	3.7	409
5	Actinobacteria: A relevant minority for the maintenance of gut homeostasis. Digestive and Liver Disease, 2018, 50, 421-428.	0.9	377
6	Gut microbiota in autism and mood disorders. World Journal of Gastroenterology, 2016, 22, 361.	3. 3	300
7	Association of Virulent <i>Helicobacter pylori</i> Strains With Ischemic Heart Disease. Circulation, 1998, 97, 1675-1679.	1.6	299
8	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of Clinical Oncology, 2021, 39, 2991-3001.	1.6	257
9	Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. Journal of Hepatology, 2019, 71, 1164-1174.	3.7	249
10	The human gut microbiota and virome: Potential therapeutic implications. Digestive and Liver Disease, 2015, 47, 1007-1012.	0.9	226
11	Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. European Journal of Cancer, 2013, 49, 3412-3419.	2.8	218
12	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study. Journal of Hepatology, 2015, 62, 617-624.	3.7	184
13	Gut microbiome, big data and machine learning to promote precision medicine for cancer. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 635-648.	17.8	172
14	The Gut Barrier. Journal of Clinical Gastroenterology, 2012, 46, S12-S17.	2.2	171
15	Extragastric Diseases and <i>Helicobacter pylori</i> . Helicobacter, 2015, 20, 40-46.	3.5	150
16	Role and mechanisms of action of <i>Escherichia coli</i> Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update. World Journal of Gastroenterology, 2016, 22, 5505.	3. 3	141
17	The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy. , 2015, 149, 191-212.		139
18	European Registry on <i>Helicobacter pylori</i> management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut, 2021, 70, 40-54.	12.1	139

#	Article	IF	Citations
19	Clinical effects of Helicobacter pylori outside the stomach. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 234-242.	17.8	137
20	Efficacy of different faecal microbiota transplantation protocols for <i>Clostridium difficile</i> infection: A systematic review and metaâ€analysis. United European Gastroenterology Journal, 2018, 6, 1232-1244.	3.8	137
21	Small Intestinal Bacterial Overgrowth: Diagnosis and Treatment. Digestive Diseases, 2007, 25, 237-240.	1.9	131
22	Intestinal Barrier in Human Health and Disease. International Journal of Environmental Research and Public Health, 2021, 18, 12836.	2.6	129
23	Identification and Management of Alcohol Withdrawal Syndrome. Drugs, 2015, 75, 353-365.	10.9	127
24	Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease Risk. Current Cardiology Reports, 2015, 17, 120.	2.9	125
25	Celiac disease and reproductive disorders: meta-analysis of epidemiologic associations and potential pathogenic mechanisms. Human Reproduction Update, 2014, 20, 582-593.	10.8	123
26	Screening of colorectal cancer: present and future. Expert Review of Anticancer Therapy, 2017, 17, 1131-1146.	2.4	123
27	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. PLoS Medicine, 2016, 13, e1002006.	8.4	113
28	Intestinal Permeability in Cirrhotic Patients With and Without Spontaneous Bacterial Peritonitis: Is the Ring Closed?. American Journal of Gastroenterology, 2010, 105, 323-327.	0.4	110
29	IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E9362-E9370.	7.1	110
30	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut, 2020, 69, 1555-1563.	12.1	110
31	The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. Digestive Diseases, 2016, 34, 269-278.	1.9	105
32	Offâ€label use of tocilizumab in patients with SARSâ€CoVâ€2 infection. Journal of Medical Virology, 2020, 92, 1787-1788.	5.0	102
33	Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. World Journal of Gastroenterology, 2019, 25, 4814-4834.	3.3	101
34	Gut Microbial, Inflammatory and Metabolic Signatures in Older People with Physical Frailty and Sarcopenia: Results from the BIOSPHERE Study. Nutrients, 2020, 12, 65.	4.1	98
35	Interaction between Lipopolysaccharide and Gut Microbiota in Inflammatory Bowel Diseases. International Journal of Molecular Sciences, 2021, 22, 6242.	4.1	98
36	Incidence of deep vein thrombosis among nonâ€lCU patients hospitalized for COVIDâ€19 despite pharmacological thromboprophylaxis. Journal of Thrombosis and Haemostasis, 2020, 18, 2358-2363.	3.8	96

#	Article	IF	Citations
37	Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. Expert Review of Gastroenterology and Hepatology, 2018, 12, 641-656.	3.0	95
38	Predicting intensive care unit admission and death for COVID-19 patients in the emergency department using early warning scores. Resuscitation, 2020, 156, 84-91.	3.0	94
39	Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology, 2021, 161, 495-507.e4.	1.3	89
40	Gut Microbiota Profiling and Gut–Brain Crosstalk in Children Affected by Pediatric Acute-Onset Neuropsychiatric Syndrome and Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections. Frontiers in Microbiology, 2018, 9, 675.	3.5	88
41	Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate. World Journal of Gastroenterology, 2016, 22, 7186.	3.3	87
42	Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients. Applied and Environmental Microbiology, 2016, 82, 6633-6644.	3.1	85
43	Increased CD95 (Fas) and PDâ€1 expression in peripheral blood T lymphocytes in COVIDâ€19 patients. British Journal of Haematology, 2020, 191, 207-211.	2.5	84
44	Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World Journal of Gastroenterology, 2019, 25, 4360-4382.	3.3	83
45	Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma. Nature Communications, 2020, 11, 4333.	12.8	82
46	Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clinical and Experimental Gastroenterology, 2015, 8, 309.	2.3	81
47	Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. Expert Review of Clinical Immunology, 2017, 13, 223-233.	3.0	78
48	Fecal Microbiota Transplantation in Inflammatory Bowel Disease. Medicine (United States), 2014, 93, e97.	1.0	77
49	Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2019, 51, 190-205.	0.9	77
50	Liver involvement is not associated with mortality: results from a large cohort of SARSâ€CoVâ€⊋â€positive patients. Alimentary Pharmacology and Therapeutics, 2020, 52, 1060-1068.	3.7	76
51	Alcoholic cardiomyopathy: What is known and what is not known. European Journal of Internal Medicine, 2017, 43, 1-5.	2.2	74
52	Can We Predict the Efficacy of Anti-TNF- \hat{l}_{\pm} Agents?. International Journal of Molecular Sciences, 2017, 18, 1973.	4.1	73
53	Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: A working hypothesis. Digestive and Liver Disease, 2020, 52, 1383-1389.	0.9	69
54	The changing scenario of hepatocellular carcinoma in Italy: an update. Liver International, 2021, 41, 585-597.	3.9	69

#	Article	IF	Citations
55	Gastric Microbiota. Helicobacter, 2015, 20, 68-71.	3.5	68
56	Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcoholâ€associated liver disease. Liver International, 2020, 40, 878-888.	3.9	68
57	Portal vein thrombosis and liver transplantation: Implications for waiting list period, surgical approach, early and late follow-up. Transplantation Reviews, 2014, 28, 92-101.	2.9	67
58	Sarilumab use in severe SARS-CoV-2 pneumonia. EClinicalMedicine, 2020, 27, 100553.	7.1	66
59	A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group. United European Gastroenterology Journal, 2021, 9, 229-247.	3.8	66
60	Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor. Journal of Clinical Medicine, 2020, 9, 1757.	2.4	65
61	Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World Journal of Gastroenterology, 2015, 21, 12322.	3.3	65
62	Lack of endoscopic visualization of intestinal villi with the "immersion technique―in overt atrophic celiac disease. Gastrointestinal Endoscopy, 2003, 57, 348-351.	1.0	64
63	Recent Insights on the Maternal Microbiota: Impact on Pregnancy Outcomes. Frontiers in Immunology, 2020, 11, 528202.	4.8	64
64	Venous thromboembolism in patients with inflammatory bowel disease: Focus on prevention and treatment. World Journal of Gastroenterology, 2014, 20, 3173.	3.3	63
65	Influence of hepatitis C virus eradication with directâ€acting antivirals on the gut microbiota in patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2018, 48, 1301-1311.	3.7	63
66	Deep Transcranial Magnetic Stimulation of the Dorsolateral Prefrontal Cortex in Alcohol Use Disorder Patients: Effects on Dopamine Transporter Availability and Alcohol Intake. European Neuropsychopharmacology, 2017, 27, 450-461.	0.7	62
67	Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver. International Journal of Molecular Sciences, 2018, 19, 2199.	4.1	62
68	Predicting <scp>Inâ€Hospital</scp> Mortality in <scp>COVID</scp> â€19 Older Patients with Specifically Developed Scores. Journal of the American Geriatrics Society, 2021, 69, 37-43.	2.6	62
69	Curcumin and Fennel Essential Oil Improve Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome. Journal of Gastrointestinal and Liver Diseases, 2020, 25, 151-157.	0.9	62
70	Liver Stiffness in Pediatric Patients with Fatty Liver Disease: Diagnostic Accuracy and Reproducibility of Shear-Wave Elastography. Radiology, 2017, 283, 820-827.	7.3	60
71	Effect of influenza vaccine on COVID-19 mortality: a retrospective study. Internal and Emergency Medicine, 2021, 16, 1849-1855.	2.0	56
72	Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy. Journal of Crohn's and Colitis, 2014, 8, 852-858.	1.3	54

#	Article	IF	CITATIONS
73	Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art. World Journal of Gastroenterology, 2016, 22, 1935.	3.3	54
74	Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma. Digestive and Liver Disease, 2015, 47, 242-248.	0.9	53
75	The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. International Journal of Molecular Sciences, 2017, 18, 2020.	4.1	53
76	Gut microbiota alteration and modulation in psychiatric disorders: Current evidence on fecal microbiota transplantation. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 109, 110258.	4.8	52
77	EUS-guided radiofrequency ablation as an alternative to surgery for pancreatic neuroendocrine neoplasms: Who should we treat?. Endoscopic Ultrasound, 2019, 8, 220.	1.5	52
78	Characterization of the gutâ€liverâ€muscle axis in cirrhotic patients with sarcopenia. Liver International, 2021, 41, 1320-1334.	3.9	51
79	Role of Yeasts in Healthy and Impaired Gut Microbiota: The Gut Mycome. Current Pharmaceutical Design, 2014, 20, 4565-4569.	1.9	51
80	The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. International Journal of Molecular Sciences, 2016, 17, 1225.	4.1	50
81	Binge Drinking among adolescents is related to the development of Alcohol Use Disorders: results from a Cross-Sectional Study. Scientific Reports, 2018, 8, 12624.	3.3	50
82	Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World Journal of Hepatology, 2017, 9, 352.	2.0	50
83	Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013–2020: Results of the European Registry on H. pylori Management (Hp-EuReg). Antibiotics, 2021, 10, 1058.	3.7	48
84	<i>Helicobacter pylori</i> infection and extragastric diseases in 2017. Helicobacter, 2017, 22, e12411.	3.5	47
85	Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591984818.	3.2	47
86	Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate. World Journal of Gastroenterology, 2019, 25, 4437-4451.	3.3	47
87	What we should know about portal vein thrombosis in cirrhotic patients: A changing perspective. World Journal of Gastroenterology, 2012, 18, 5014.	3.3	46
88	Review: Extragastric diseases and <i>Helicobacter pylori </i> . Helicobacter, 2020, 25, e12741.	3.5	45
89	Autologous faecal microbiota transplantation for type 1 diabetes: a potential mindshift in therapeutic microbiome manipulation?. Gut, 2021, 70, 2-3.	12.1	45
90	Transradial versus Transfemoral Access for Hepatic Chemoembolization: Intrapatient Prospective Single-Center Study. Journal of Vascular and Interventional Radiology, 2017, 28, 1234-1239.	0.5	44

#	Article	IF	Citations
91	Role of Microbiota and Innate Immunity in Recurrent <i>Clostridium difficile</i> Infection. Journal of Immunology Research, 2014, 2014, 1-8.	2.2	43
92	The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey. Lancet Regional Health - Europe, The, 2021, 9, 100181.	5.6	43
93	Tumor Initiating Cells and Chemoresistance: Which Is the Best Strategy to Target Colon Cancer Stem Cells?. BioMed Research International, 2014, 2014, 1-7.	1.9	41
94	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. Liver International, 2019, 39, 1478-1489.	3.9	41
95	Gastrointestinal involvement of autism spectrum disorder: focus on gut microbiota. Expert Review of Gastroenterology and Hepatology, 2021, 15, 599-622.	3.0	41
96	Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk. Gastroenterology Research and Practice, 2015, 2015, 1-5.	1.5	40
97	Diagnosis and treatment of small intestinal bacterial overgrowth. Expert Review of Gastroenterology and Hepatology, 2016, 10, 215-227.	3.0	40
98	COVID-19 and intestinal inflammation: Role of fecal calprotectin. Digestive and Liver Disease, 2020, 52, 1231-1233.	0.9	40
99	Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut–Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. International Journal of Molecular Sciences, 2021, 22, 6485.	4.1	40
100	The gastrointestinal microbiome – Functional interference between stomach and intestine. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 995-1002.	2.4	39
101	Gut Virome and Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 1708-1712.	1.9	39
102	The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer. International Journal of Molecular Sciences, 2019, 20, 501.	4.1	39
103	European Registry on <i>Helicobacter pylori</i> management: Singleâ€capsule bismuth quadruple therapy is effective in realâ€world clinical practice. United European Gastroenterology Journal, 2021, 9, 38-46.	3.8	39
104	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. Journal of Gastrointestinal Surgery, 2018, 22, 859-871.	1.7	38
105	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. Journal of Hepatology, 2021, 74, 340-349.	3.7	38
106	Proteomics and Metabolomics Approaches towards a Functional Insight onto AUTISM Spectrum Disorders: Phenotype Stratification and Biomarker Discovery. International Journal of Molecular Sciences, 2020, 21, 6274.	4.1	37
107	Dual Targeted Therapy: A Possible Option for the Management of Refractory Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 335-339.	1.3	37
108	The gutâ€"brain axis in irritable bowel syndrome and inflammatory bowel disease. Digestive and Liver Disease, 2021, 53, 298-305.	0.9	37

#	Article	IF	Citations
109	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). Internal and Emergency Medicine, 2021, 16, 1005-1015.	2.0	37
110	COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms. World Journal of Gastroenterology, 2021, 27, 7433-7445.	3.3	37
111	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2019, 51, 632-639.	0.9	36
112	Endoscopic Management of Benign Biliary Strictures After Liver Transplantation. Liver Transplantation, 2019, 25, 323-335.	2.4	36
113	Assessment of neurological manifestations in hospitalized patients with COVID‶9. European Journal of Neurology, 2020, 27, 2322-2328.	3.3	36
114	Performance of a new needle for endoscopic ultrasound-guided fine-needle biopsy in patients with pancreatic solid lesions: A retrospective multicenter study. Endoscopic Ultrasound, 2018, 7, 329.	1.5	36
115	NutriCatt protocol in the Enhanced Recovery After Surgery (ERAS) program for colorectal surgery: The nutritional support improves clinical and cost-effectiveness outcomes. Nutrition, 2018, 50, 74-81.	2.4	35
116	Assessment of preoperative nutritional status using BIA-derived phase angle (PhA) in patients with advanced ovarian cancer: Correlation with the extent of cytoreduction and complications. Gynecologic Oncology, 2018, 149, 263-269.	1.4	35
117	A network metaâ€nnalysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent <i>Clostridium difficile</i> infection. United European Gastroenterology Journal, 2019, 7, 1051-1063.	3.8	35
118	Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. The Lancet Gastroenterology and Hepatology, 2020, 5, 1063-1075.	8.1	35
119	Food Additives, Gut Microbiota, and Irritable Bowel Syndrome: A Hidden Track. International Journal of Environmental Research and Public Health, 2020, 17, 8816.	2.6	35
120	The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications. Inflammatory Bowel Diseases, 2020, 26, 1306-1314.	1.9	35
121	Gut Microbiota during Dietary Restrictions: New Insights in Non-Communicable Diseases. Microorganisms, 2020, 8, 1140.	3.6	35
122	Interventional endoscopic ultrasound for pancreatic neuroendocrine neoplasms. Digestive Endoscopy, 2020, 32, 1031-1041.	2.3	35
123	The Role of Nutrition in the COVID-19 Pandemic. Nutrients, 2021, 13, 1093.	4.1	35
124	COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+ monocytes. JCI Insight, 2021, 6, .	5.0	35
125	Food Additives, a Key Environmental Factor in the Development of IBD through Gut Dysbiosis. Microorganisms, 2022, 10, 167.	3.6	35
126	Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer. Critical Reviews in Oncology/Hematology, 2018, 129, 54-66.	4.4	34

#	Article	IF	Citations
127	Diet and Nutrients in Gastrointestinal Chronic Diseases. Nutrients, 2020, 12, 2693.	4.1	34
128	Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110066.	3.2	34
129	Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy. Autoimmunity Reviews, 2021, 20, 102832.	5.8	34
130	EUS-guided fine-needle tissue acquisition for solid pancreatic lesions: Finally moving from fine-needle aspiration to fine-needle biopsy?. Endoscopic Ultrasound, 2018, 7, 137.	1.5	34
131	Alcohol addiction - the safety of available approved treatment options. Expert Opinion on Drug Safety, 2018, 17, 169-177.	2.4	33
132	Forecasting Hepatitis C liver disease burden on realâ€ife data. Does the <i>hidden iceberg</i> matter to reach the elimination goals?. Liver International, 2018, 38, 2190-2198.	3.9	33
133	Predictors of in-hospital mortality AND death RISK STRATIFICATION among COVID-19 PATIENTS aged ≥ 80 YEARs OLD. Archives of Gerontology and Geriatrics, 2021, 95, 104383.	3.0	33
134	Endoscopic tools for the diagnosis and evaluation of celiac disease. World Journal of Gastroenterology, 2013, 19, 8562.	3.3	32
135	Frailty Assessment in the Emergency Department for Risk Stratification of COVID-19 Patients Aged ≥80ÂYears. Journal of the American Medical Directors Association, 2021, 22, 1845-1852.e1.	2.5	32
136	Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for †gut barrier protectors' in IBD?. United European Gastroenterology Journal, 2014, 2, 113-122.	3.8	31
137	The gut microbiota and colorectal surgery outcomes: facts or hype? A narrative review. BMC Surgery, 2021, 21, 83.	1.3	31
138	Double-balloon enteroscopy for diagnosis of a Meckel's diverticulum in a patient with GI bleeding of obscure origin. Gastrointestinal Endoscopy, 2005, 61, 779-781.	1.0	29
139	Irritable Bowel Syndrome and Nickel Allergy: What Is the Role of the Low Nickel Diet?. Journal of Neurogastroenterology and Motility, 2017, 23, 101-108.	2.4	29
140	Liver Injury, Endotoxemia, and Their Relationship to Intestinal Microbiota Composition in Alcoholâ€Preferring Rats. Alcoholism: Clinical and Experimental Research, 2018, 42, 2313-2325.	2.4	29
141	Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic. Journal of Ultrasound, 2020, 23, 449-456.	1.3	29
142	Fecal transplantation for ulcerative colitis: current evidence and future applications. Expert Opinion on Biological Therapy, 2020, 20, 343-351.	3.1	29
143	The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. CNS Drugs, 2021, 35, 861-880.	5.9	29
144	Liver transplantation for severe alcoholic hepatitis: A multicenter Italian study. American Journal of Transplantation, 2022, 22, 1191-1200.	4.7	29

#	Article	IF	CITATIONS
145	Prevention and Treatment of Venous Thromboembolism in Patients with IBD. Inflammatory Bowel Diseases, 2015, 21, 1204-1213.	1.9	28
146	Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. Liver International, 2016, 36, 1033-1042.	3.9	28
147	Non-specific gastrointestinal features: Could it be Fabry disease?. Digestive and Liver Disease, 2018, 50, 429-437.	0.9	28
148	Enhanced Liver Fibrosis Test as a Reliable Tool for Assessing Fibrosis in Nonalcoholic Fatty Liver Disease in a Clinical Setting. International Journal of Biological Markers, 2017, 32, 397-402.	1.8	27
149	Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn's Disease. Digestive Diseases, 2018, 36, 184-193.	1.9	27
150	Outcomes of Lower Extremity Endovascular Revascularization: Potential Predictors and Prevention Strategies. International Journal of Molecular Sciences, 2021, 22, 2002.	4.1	27
151	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. Hepatology, 2018, 68, 1232-1244.	7.3	26
152	Gut Microbiome and Common Variable Immunodeficiency: Few Certainties and Many Outstanding Questions. Frontiers in Immunology, 2021, 12, 712915.	4.8	26
153	Rifaximin-Based Regimens for Eradication of <i>Helicobacter pylori</i> : A Pilot Study. Digestive Diseases, 2006, 24, 195-200.	1.9	25
154	Eradication of <i>Helicobacter pylori</i> : Are Rifaximin-Based Regimens Effective?. Digestion, 2006, 73, 129-135.	2.3	25
155	Human leukocyte antigen (HLA) DQ2/DQ8 prevalence in recurrent pregnancy loss women. Autoimmunity Reviews, 2016, 15, 638-643.	5.8	25
156	Risk, prevalence, and impact of hospital malnutrition in a Tertiary Care Referral University Hospital: a cross-sectional study. Internal and Emergency Medicine, 2018, 13, 689-697.	2.0	25
157	The Use of Probiotics in Different Phases of Diverticular Disease. Reviews on Recent Clinical Trials, 2018, 13, 89-96.	0.8	25
158	Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use. PLoS ONE, 2021, 16, e0245281.	2.5	25
159	<i>Helicobacter pylori</i> and Extragastric Diseases – Other <i>Helicobacters</i> . Helicobacter, 2004, 9, 57-66.	3.5	24
160	New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. Digestive and Liver Disease, 2018, 50, 741-749.	0.9	24
161	Bariatric Surgery and Liver Disease: General Considerations and Role of the Gut–Liver Axis. Nutrients, 2021, 13, 2649.	4.1	24
162	Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment. World Journal of Hepatology, 2015, 7, 1866.	2.0	24

#	Article	IF	Citations
163	Microbiota in Pancreatic Diseases: A Review of the Literature. Journal of Clinical Medicine, 2021, 10, 5920.	2.4	24
164	Bacillus clausii and gut homeostasis: state of the art and future perspectives. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1-6.	3.0	23
165	Usefulness of contrast-enhanced ultrasound (CEUS) in Inflammatory Bowel Disease (IBD). Digestive and Liver Disease, 2018, 50, 761-767.	0.9	23
166	Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2020, 112, 154355.	3.4	23
167	Towards a disease-associated common trait of gut microbiota dysbiosis: The pivotal role of Akkermansia muciniphila. Digestive and Liver Disease, 2020, 52, 1002-1010.	0.9	23
168	Gut and Reproductive Tract Microbiota Adaptation during Pregnancy: New Insights for Pregnancy-Related Complications and Therapy. Microorganisms, 2021, 9, 473.	3.6	23
169	Residual respiratory impairment after COVID-19 pneumonia. BMC Pulmonary Medicine, 2021, 21, 241.	2.0	23
170	Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2021, 10, 853.	2.4	22
171	Nonlinear machine learning pattern recognition and bacteria-metabolite multilayer network analysis of perturbed gastric microbiome. Nature Communications, 2021, 12, 1926.	12.8	22
172	Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma. Journal of Hepatology, 2021, 75, 1387-1396.	3.7	22
173	Gut Microbiota and Cardiovascular Diseases. Cardiology in Review, 2021, 29, 195-204.	1.4	22
174	Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin. Mini-Reviews in Medicinal Chemistry, 2015, 16, 179-185.	2.4	22
175	Fecal microbiota transplantation: past, present and future perspectives. Minerva Gastroenterology, 2017, 63, 420-430.	0.5	22
176	ToF-SIMS and principal component analysis of lipids and amino acids from inflamed and dysplastic human colonic mucosa. Analytical and Bioanalytical Chemistry, 2017, 409, 6097-6111.	3.7	21
177	Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2020, 115, 1722-1724.	0.4	21
178	Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets. Translational Research, 2021, 231, 24-38.	5.0	21
179	Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center. Gut Microbes, 2021, 13, 1994834.	9.8	21
180	A Natural Diet Versus Modern Western Diets? A New Approach to Prevent ?Well-Being Syndromes?. Digestive Diseases and Sciences, 2005, 50, 1-6.	2.3	20

#	Article	IF	Citations
181	Endometriosis and atherosclerosis: what we already know and what we have yet to discover. American Journal of Obstetrics and Gynecology, 2015, 213, 326-331.	1.3	20
182	Lactose intolerance genetic testing: Is it useful as routine screening? Results on 1426 south–central Italy patients. Clinica Chimica Acta, 2015, 439, 14-17.	1.1	20
183	<i>Helicobacter pylori</i> infection contributes to placental impairment in preeclampsia: basic and clinical evidences. Helicobacter, 2017, 22, e12347.	3.5	20
184	Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Annals of Hepatology, 2018, 17, 110-118.	1.5	20
185	Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD). Clinical Epigenetics, 2020, 12, 126.	4.1	20
186	Liver Injury in Patients Hospitalized for COVID-19: Possible Role of Therapy. Vaccines, 2022, 10, 192.	4.4	20
187	Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy. ClinicoEconomics and Outcomes Research, 2014, 6, 303.	1.9	19
188	Prior Misdiagnosis of Celiac Disease Is Common Among Patients Referred to a Tertiary Care Center: A Prospective Cohort Study. Clinical and Translational Gastroenterology, 2016, 7, e139.	2.5	19
189	Baclofen for the Treatment of Alcohol Use Disorder in Patients With Liver Cirrhosis: 10 Years After the First Evidence. Frontiers in Psychiatry, 2018, 9, 474.	2.6	19
190	Angiotensinâ€converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID 9. Internal Medicine Journal, 2020, 50, 1483-1491.	0.8	19
191	Dietary Habits and Gut Microbiota in Healthy Adults: Focusing on the Right Diet. A Systematic Review. International Journal of Molecular Sciences, 2021, 22, 6728.	4.1	19
192	Performance of a new histology needle for EUS-guided fine needle biopsy: A retrospective multicenter study. Digestive and Liver Disease, 2018, 50, 469-474.	0.9	18
193	Faecal microbiota transplantation in clinical practice. Gut, 2018, 67, 196.2-197.	12.1	18
194	Anticoagulant therapy in the treatment of splanchnic vein thrombosis associated to acute pancreatitis: a 3-year single-centre experience. Internal and Emergency Medicine, 2020, 15, 1021-1029.	2.0	18
195	Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders. Future Microbiology, 2020, 15, 1173-1183.	2.0	18
196	Pattern of macrovascular invasion in hepatocellular carcinoma. European Journal of Clinical Investigation, 2021, 51, e13542.	3.4	18
197	Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Digestive and Liver Disease, 2014, 46, 936-942.	0.9	17
198	The Effect of <i>CYP, GST, </i> and <i>SULT </i> Polymorphisms and Their Interaction with Smoking on the Risk of Hepatocellular Carcinoma. BioMed Research International, 2015, 2015, 1-7.	1.9	17

#	Article	IF	Citations
199	High prevalence of constipation and reduced quality of life in opioid-dependent patients treated with opioid substitution treatments. Expert Opinion on Pharmacotherapy, 2016, 17, 2135-2141.	1.8	17
200	Direct effect of infliximab on intestinal mucosa sustains mucosal healing: exploring new mechanisms of action. Digestive and Liver Disease, 2016, 48, 391-398.	0.9	17
201	Regorafenib: a promising treatment for hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2018, 19, 1941-1948.	1.8	17
202	The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn's disease. Expert Opinion on Investigational Drugs, 2018, 27, 543-551.	4.1	17
203	Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges. Nutrients, 2020, 12, 3101.	4.1	17
204	COVIDâ€19 and hepatic involvement: The liver as a main actor of the pandemic novel. Scandinavian Journal of Immunology, 2021, 93, e12977.	2.7	17
205	Impact of Food Additive Titanium Dioxide on Gut Microbiota Composition, Microbiota-Associated Functions, and Gut Barrier: A Systematic Review of In Vivo Animal Studies. International Journal of Environmental Research and Public Health, 2021, 18, 2008.	2.6	17
206	Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: Serum sodium predicts survival. World Journal of Gastroenterology, 2014, 20, 8158.	3.3	17
207	New semiquantitative ultrasonographic score for peripheral arterial disease assessment and its association with cardiovascular risk factors. Hypertension Research, 2016, 39, 868-873.	2.7	16
208	Real-time diagnosis of <i>H. pylori</i> infection during endoscopy: Accuracy of an innovative tool (EndoFaster). United European Gastroenterology Journal, 2016, 4, 339-342.	3.8	16
209	Contrast-enhanced ultrasound patterns of hepatocellular adenoma: an Italian multicenter experience. Journal of Ultrasound, 2019, 22, 157-165.	1.3	16
210	Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: A prospective cohort study. Digestive and Liver Disease, 2020, 52, 1390-1395.	0.9	16
211	Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study. Nutrients, 2021, 13, 960.	4.1	16
212	Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. Journal of Clinical and Translational Hepatology, 2017, XX, 1-14.	1.4	16
213	The gut microbiota: its anatomy and physiology over a lifetime. Minerva Gastroenterology, 2017, 63, 329-336.	0.5	16
214	Nutrients Affecting Gastric Barrier. Digestive Diseases, 2014, 32, 243-248.	1.9	15
215	The use of single balloon enteroscopy in Crohn's disease and its impact on clinical outcome. Scandinavian Journal of Gastroenterology, 2018, 53, 925-929.	1.5	15
216	Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug. United European Gastroenterology Journal, 2019, 7, 1408-1410.	3.8	15

#	Article	IF	Citations
217	TRPM7 is overexpressed in human IBD-related and sporadic colorectal cancer and correlates with tumor grade. Digestive and Liver Disease, 2020, 52, 1188-1194.	0.9	15
218	Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. Journal of Hepatology, 2021, 75, 1355-1366.	3.7	15
219	Vitamin D and colorectal cancer: Chemopreventive perspectives through the gut microbiota and the immune system. BioFactors, 2022, 48, 285-293.	5.4	15
220	A case of granulocyteâ€colony stimulating factor/plasmapheresis–induced activation of granulocyteâ€colony stimulating factor–positive hepatic progenitors in acuteâ€onâ€chronic liver failure. Hepatology, 2015, 62, 649-652.	7.3	14
221	Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases. Expert Review of Clinical Immunology, 2018, 14, 751-759.	3.0	14
222	Risk factors for gastric cancer: is it time to discard PPIs?. Gut, 2019, 68, 176-177.	12.1	14
223	Energy drinks: a narrative review of their physiological and pathological effects. Internal Medicine Journal, 2021, 51, 636-646.	0.8	14
224	Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence. Journal of Personalized Medicine, $2021,11,265.$	2.5	14
225	A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19. Scientific Reports, 2021, 11, 21136.	3.3	14
226	A metaproteomic-based gut microbiota profiling in children affected by autism spectrum disorders. Journal of Proteomics, 2022, 251, 104407.	2.4	14
227	Acute refractory intestinal pseudo-obstruction in MELAS: Efficacy of prucalopride. Neurology, 2014, 82, 1932-1934.	1.1	13
228	Team work and cytopathology molecular diagnosis of solid pancreatic lesions. Digestive Endoscopy, 2017, 29, 657-666.	2.3	13
229	The impact of personalized nutritional support on postoperative outcome within the enhanced recovery after surgery (ERAS) program for liver resections: results from the NutriCatt protocol. Updates in Surgery, 2020, 72, 681-691.	2.0	13
230	Anorectal Function and Quality of Life in IBD Patients With A Perianal Complaint. Journal of Investigative Surgery, 2021, 34, 547-553.	1.3	13
231	Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. Journal of Cancer Research and Clinical Oncology, 2022, 148, 475-485.	2.5	13
232	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. International Journal of Clinical Practice, 2021, 75, e14755.	1.7	13
233	Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma. Cancers, 2022, 14, 481.	3.7	13
234	Is there a role for anticoagulants in portal vein thrombosis management in cirrhotic patients?. Expert Opinion on Pharmacotherapy, 2010, 11, 1479-1487.	1.8	12

#	Article	IF	Citations
235	Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. Clinical Epidemiology, 2018, Volume 10, 203-213.	3.0	12
236	Considering gut microbiota disturbance in the management of Helicobacter pylori infection. Expert Review of Gastroenterology and Hepatology, 2018, 12, 899-906.	3.0	12
237	Association between carotid plaque vulnerability and high mobility group box-1 serum levels in a diabetic population. Cardiovascular Diabetology, 2021, 20, 114.	6.8	12
238	Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives. Journal of Clinical Medicine, 2021, 10, 2605.	2.4	12
239	Role of gut microbiome on immunotherapy efficacy in melanoma. Human Vaccines and Immunotherapeutics, 2022, $18,1$ -6.	3.3	12
240	Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach. Italian Journal of Pediatrics, 2021, 47, 18.	2.6	12
241	Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis. Internal and Emergency Medicine, 2021, 16, 1341-1356.	2.0	12
242	Humoral Predictors of Malignancy in IPMN: A Review of the Literature. International Journal of Molecular Sciences, 2021, 22, 12839.	4.1	12
243	Clinical Impact of Nutritional Status and Sarcopenia in Pediatric Patients with Bone and Soft Tissue Sarcomas: A Pilot Retrospective Study (SarcoPed). Nutrients, 2022, 14, 383.	4.1	12
244	Current technologies for the endoscopic assessment of duodenal villous pattern in celiac disease. Computers in Biology and Medicine, 2015, 65, 308-314.	7.0	11
245	Nutritional Support in Lung Cancer Patients: The State of the Art. Clinical Lung Cancer, 2021, 22, e584-e594.	2.6	11
246	Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy. Nutrients, 2020, 12, 3277.	4.1	11
247	Bowel contrast-enhanced ultrasound perfusion imaging in the evaluation of Crohn's disease patients undergoing anti-TNFî± therapy. Digestive and Liver Disease, 2021, 53, 729-737.	0.9	11
248	Endoscopic ultrasound-guided therapies for pancreatic solid tumors: An overview. Seminars in Oncology, 2021, 48, 95-105.	2.2	11
249	Helicobacter pylori in metabolic related diseases. Minerva Gastroenterologica E Dietologica, 2018, 64, 297-309.	2.2	11
250	Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib. Cancer Imaging, 2022, 22, 1.	2.8	11
251	Circulating hematopoietic stem cells and putative intestinal stem cells in coeliac disease. Journal of Translational Medicine, 2015, 13, 220.	4.4	10
252	Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opinion on Pharmacotherapy, 2016, 17, 1395-1402.	1.8	10

#	Article	IF	CITATIONS
253	Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leukemia and Lymphoma, 2017, 58, 993-995.	1.3	10
254	<i>XRCC1</i> Arg399Gln Gene Polymorphism and Hepatocellular Carcinoma Risk in the Italian Population. International Journal of Biological Markers, 2017, 32, 190-194.	1.8	10
255	Liver Transplantation in Patients with Alcoholic Liver Disease: A Retrospective Study. Alcohol and Alcoholism, 2018, 53, 151-156.	1.6	10
256	Metabolic disorders across hepatocellular carcinoma in Italy. Liver International, 2018, 38, 2028-2039.	3.9	10
257	Antithrombotic Therapy in Hereditary Hemorrhagic Telangiectasia: Real-World Data from the Gemelli Hospital HHT Registry. Journal of Clinical Medicine, 2020, 9, 1699.	2.4	10
258	Acute Diverticulitis in Elderly Patients: Does Age Really Matter?. Digestive Diseases, 2021, 39, 33-41.	1.9	10
259	Monofocal hepatocellular carcinoma: How much does size matter?. Liver International, 2021, 41, 396-407.	3.9	10
260	Donor program for fecal microbiota transplantation: A 3-year experience of a large-volume Italian stool bank. Digestive and Liver Disease, 2021, 53, 1428-1432.	0.9	10
261	Gastrointestinal Manifestations in Hereditary Transthyretin Amyloidosis: a Single-Centre Experience. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 339-343.	0.9	10
262	Improved gut microbiota features after the resolution of SARS‑CoV‑2 infection. Gut Pathogens, 2021, 13, 62.	3.4	10
263	The prognostic value of skeletal muscle index on clinical and survival outcomes after cytoreduction and HIPEC for peritoneal metastases from colorectal cancer: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2022, 48, 649-656.	1.0	10
264	Dietary Magnesium Alleviates Experimental Murine Colitis through Modulation of Gut Microbiota. Nutrients, 2021, 13, 4188.	4.1	10
265	Frailty Assessment in the Emergency Department for Patients ≥80ÂYears Undergoing Urgent Major Surgical Procedures. Journal of the American Medical Directors Association, 2022, 23, 581-588.	2.5	10
266	Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. Internal and Emergency Medicine, 2016, 11, 3-10.	2.0	9
267	Enterography CT without and with water enema in patients with Crohn's disease: Results from a comparative observational study in comparison with endoscopy. European Journal of Radiology, 2016, 85, 404-413.	2.6	9
268	Early oral vs parenteral nutrition in acute pancreatitis: a retrospective analysis of clinical outcomes and hospital costs from a tertiary care referral center. Internal and Emergency Medicine, 2020, 15, 613-619.	2.0	9
269	Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. Alimentary Pharmacology and Therapeutics, 2020, 52, 902-903.	3.7	9
270	Management of acute cholecystitis in elderly patients: A propensity score-matched analysis of surgical vs. medical treatment. Digestive and Liver Disease, 2021, 53, 1620-1626.	0.9	9

#	Article	IF	CITATIONS
271	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. Cancers, 2021, 13, 897.	3.7	9
272	Anti-TNF-Related Leukocytoclastic Vasculitis in Ulcerative Colitis: A Case Report. International Journal of Environmental Research and Public Health, 2021, 18, 6711.	2.6	9
273	Endorotor-Based Endoscopic Necrosectomy as a Rescue or Primary Treatment of Complicated Walled-off Pancreatic Necrosis. A Case Series. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 681-684.	0.9	9
274	Vaccines, Microbiota and Immunonutrition: Food for Thought. Vaccines, 2022, 10, 294.	4.4	9
275	Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors. Digestive and Liver Disease, 2015, 47, 351-355.	0.9	8
276	Does high-dose benzodiazepine abuse really produce liver toxicity? Results from a series of 201 benzodiazepine monoabusers. Expert Opinion on Drug Safety, 2018, 17, 451-456.	2.4	8
277	Fecal calprotectin in management of <i>Clostridium difficile</i> infection: a longitudinal study. Scandinavian Journal of Gastroenterology, 2018, 53, 567-572.	1.5	8
278	Microparticles Produced by Activated Platelets Carry a Potent and Functionally Active Angiogenic Signal in Subjects with Crohn's Disease. International Journal of Molecular Sciences, 2018, 19, 2921.	4.1	8
279	Epidemiology of inflammatory bowel disease in the Republic of San Marino: The "EPIMICI – San Marino― study. Digestive and Liver Disease, 2019, 51, 218-225.	0.9	8
280	Real life experiences in HCV management in 2018. Expert Review of Anti-Infective Therapy, 2019, 17, 117-128.	4.4	8
281	Confirmed or unconfirmed cases of 2019 novel coronavirus pneumonia in Italian patients: a retrospective analysis of clinical features. BMC Infectious Diseases, 2020, 20, 775.	2.9	8
282	It $\hat{a} \in \mathbb{T}^M$ s how we communicate! Exploring face-to-face versus electronic communication networks in multidisciplinary teams. Health Care Management Review, 2021, 46, 153-161.	1.4	8
283	Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. International Journal of Biological Markers, 2021, 36, 54-61.	1.8	8
284	Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study. Breast, 2021, 60, 6-14.	2.2	8
285	Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study. Scientific Reports, 2019, 9, 15373.	3.3	7
286	Zolpidem high-dose abuse: what about the liver? Results from a series of 107 patients. Expert Opinion on Drug Safety, 2019, 18, 753-758.	2.4	7
287	A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohn's disease patients. Expert Review of Gastroenterology and Hepatology, 2020, 14, 857-865.	3.0	7
288	Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2103-2110.	2.6	7

#	Article	IF	Citations
289	Letter: faecal microbiota transplantation for irritable bowel syndrome—room for improvement. Alimentary Pharmacology and Therapeutics, 2020, 52, 923-924.	3.7	7
290	Effect of liver transplantation on intestinal permeabilityÂand correlation with infection episodes. PLoS ONE, 2020, 15, e0235359.	2.5	7
291	Contrast-Enhanced Ultrasound in the Short-Term Evaluation of Hepatocellular Carcinoma after Locoregional Treatment. Digestive Diseases, 2020, 38, 522-533.	1.9	7
292	Real-life survey on severe asthma patients during COVID-19 lockdown in Italy. Expert Review of Respiratory Medicine, 2021, 15, 1057-1060.	2.5	7
293	The role of elastography in non-alcoholic fatty liver disease. Minerva Gastroenterology, 2021, 67, 164-170.	0.5	7
294	Does chronic oral anticoagulation reduce in-hospital mortality among COVID-19 older patients?. Aging Clinical and Experimental Research, 2021, 33, 2335-2343.	2.9	7
295	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study Digestive and Liver Disease, 2021, 53, 1011-1019.	0.9	7
296	Barrett's oesophagus and associated dysplasia are not equally distributed within the esophageal circumference. Digestive and Liver Disease, 2016, 48, 1043-1047.	0.9	6
297	Treatment of early stage chronic hepatitis C virus infection. Expert Review of Clinical Pharmacology, 2018, 11, 519-524.	3.1	6
298	Lack of reduction in serum alphaâ€fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virusâ€related cirrhosis. Journal of Viral Hepatitis, 2018, 25, 1493-1500.	2.0	6
299	ACE I allele is associated with more severe portal hypertension in patients with liver cirrhosis: A pilot study. Digestive and Liver Disease, 2019, 51, 293-296.	0.9	6
300	Make Mission Impossible Feasible: The Experience of a Multidisciplinary Team Providing Treatment for Alcohol Use Disorder to Homeless Individuals. Alcohol and Alcoholism, 2020, 55, 547-553.	1.6	6
301	"Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial― Trials, 2020, 21, 875.	1.6	6
302	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. Digestive and Liver Disease, 2021, 53, 612-619.	0.9	6
303	Basophil activation and serum ILâ€5 levels as possible monitor biomarkers in severe eosinophilic asthma patients treated with antiâ€ILâ€5 drugs. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1569-1571.	5.7	6
304	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Liver Cancer, 2021, 10, 126-136.	7.7	6
305	Clinical characteristics of metabolic associated fatty liver disease (MAFLD) in subjects with myotonic dystrophy type 1 (DM1). Digestive and Liver Disease, 2021, 53, 1451-1457.	0.9	6
306	Early Procalcitonin Assessment in the Emergency Department in Patients with Intra-Abdominal Infection: An Excess or a Need?. Surgical Infections, 2021, 22, 787-796.	1.4	6

#	Article	IF	Citations
307	Correlation Between Liver Function Tests Abnormalities and Interleukin-6 Serum Levels in Patients With SARS-CoV-2 Infection. Gastroenterology, 2021, 160, 1891-1893.	1.3	6
308	Delta-Procalcitonin and Vitamin D Can Predict Mortality of Internal Medicine Patients with Microbiological Identified Sepsis. Medicina (Lithuania), 2021, 57, 331.	2.0	6
309	A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. Cancers, 2021, 13, 2677.	3.7	6
310	Nutritional Interventions Targeting Gut Microbiota during Cancer Therapies. Microorganisms, 2021, 9, 1469.	3.6	6
311	COVIDâ€19, adaptative immune response and metabolicâ€associated liver disease. Liver International, 2021, 41, 2560-2577.	3.9	6
312	Echocardiographic markers of early alcoholic cardiomyopathy: Six-month longitudinal study in heavy drinking patients. European Journal of Internal Medicine, 2022, 101, 76-85.	2.2	6
313	Helicobacter pylori and small intestinal bacterial overgrowth affect gastrointestinal symptoms in Fabry's disease. Digestive and Liver Disease, 2015, 47, 618-619.	0.9	5
314	Endoscopic Ultrasound for the Hepatologist: A Comprehensive Review. Seminars in Liver Disease, 2018, 38, 145-159.	3.6	5
315	Takotsubo Syndrome and Inflammatory Bowel Diseases: Does a Link Exist?. Digestive Diseases, 2020, 38, 204-210.	1.9	5
316	Fecal calprotectin and need of multiple microbiota trasplantation infusions in Clostridium difficile infection. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1909-1915.	2.8	5
317	Impact of the Trophic Effects of the Secretome From a Multistrain Probiotic Preparation on the Intestinal Epithelia. Inflammatory Bowel Diseases, 2021, 27, 902-913.	1.9	5
318	Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project. Journal of Viral Hepatitis, 2021, 28, 651-656.	2.0	5
319	Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs. Cancers, 2021, 13, 592.	3.7	5
320	Advances in pharmacotherapeutics for hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2021, 22, 1343-1354.	1.8	5
321	The Healthy Gluten-Free Diet: Practical Tips to Prevent Metabolic Disorders and Nutritional Deficiencies in Celiac Patients. Gastroenterology Insights, 2021, 12, 166-182.	1.2	5
322	SARS-CoV-2 vaccines and donor recruitment for FMT. The Lancet Gastroenterology and Hepatology, 2021, 6, 264-266.	8.1	5
323	Correlation Between <scp>QElaXto</scp> Techniques and Supersonic Imagine for Liver Stiffness Quantification in Chronic Liver Disease. Journal of Ultrasound in Medicine, 2022, 41, 877-886.	1.7	5
324	Winter Is Coming and COVID-19 Vaccine Is Available! The Role of Gastroenterologist in Increasing COVID-19 Vaccine Acceptability Among IBD Patients. Gastroenterology, 2021, 161, 368-369.	1.3	5

#	Article	IF	CITATIONS
325	Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial. European Radiology, 2022, 32, 1320-1329.	4.5	5
326	Metabolomics, Microbiota, and In Vivo and In Vitro Biomarkers in Type 2 Severe Asthma: A Perspective Review. Metabolites, 2021, 11, 647.	2.9	5
327	Infliximab does not increase colonic cancer risk associated to murine chronic colitis. World Journal of Gastroenterology, 2016, 22, 9727.	3.3	5
328	Resectable pancreatic solid lesions: Time to move from surgical diagnosis?. Endoscopic Ultrasound, 2020, 9, 76.	1.5	5
329	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. Frontiers in Oncology, 2022, 12, 822507.	2.8	5
330	†Hug sign': a new radiological sign of intraprocedural success after combined treatment for hepatocellular carcinoma. Hepatic Oncology, 2017, 4, 69-73.	4.2	4
331	Endoscopic necrosectomy through a lumen-apposing metal stent resulting in perforation: is it time to develop dedicated accessories?. Endoscopy, 2017, 50, 79-80.	1.8	4
332	Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time?. Digestive Diseases and Sciences, 2017, 62, 2220-2222.	2.3	4
333	Predictors of mortality of bloodstream infections among internal medicine patients: Mind the complexity of the septic population!. European Journal of Internal Medicine, 2019, 68, e22-e23.	2.2	4
334	Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482096874.	3.2	4
335	A new ultrasound score for the assessment and follow-up of chronic pancreatitis: The †Gemelli USCP score'. Digestive and Liver Disease, 2020, 52, 644-650.	0.9	4
336	Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2022, 20, e1483-e1487.	4.4	4
337	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk―patients does not further improve survival. Digestive and Liver Disease, 2022, 54, 927-936.	0.9	4
338	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. European Journal of Cancer, 2021, 158, 133-143.	2.8	4
339	Gastroenterology training in Europe: unmet educational needs beyond the machines. Gut, 2016, 65, 185-187.	12.1	3
340	Therapy experiences and preferences among patients with anemia: Results of a cross-sectional survey among Italian patients with inflammatory bowel disease. Digestive and Liver Disease, 2017, 49, 1098-1103.	0.9	3
341	Eosinophilic oesophagitis (in nickel-allergic patient) regressed after nickel oral desensitization: A case report. International Journal of Immunopathology and Pharmacology, 2019, 33, 205873841982777.	2.1	3
342	Impact evaluation of a Critical Pathway for patients with Clostridium difficile infection: A pre-post analysis in a Third Level Referral Center. International Journal of Infectious Diseases, 2019, 80, 105-110.	3.3	3

#	Article	IF	CITATIONS
343	Management of celiac disease in daily clinical practice: do not forget depression!. European Journal of Internal Medicine, 2019, 62, e17.	2.2	3
344	Coeliac disease under a microscope: Histological diagnostic features and confounding factors. Computers in Biology and Medicine, 2019, 104, 335-338.	7.0	3
345	Wernicke's Encephalopathy in Alcohol Use Disorder Patients after Liver Transplantation: A Case Series and Review of Literature. Journal of Clinical Medicine, 2020, 9, 3809.	2.4	3
346	"Primum Non Nocere―in Interventional Oncology for Liver Cancer: How to Reduce the Risk for Complications?. Life, 2020, 10, 180.	2.4	3
347	Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness, safety and immunogenicity in a large cohort of IBD patients. Expert Opinion on Biological Therapy, 2021, 21, 97-104.	3.1	3
348	Profiling the Gastrointestinal Microbiota. Methods in Molecular Biology, 2021, 2283, 83-92.	0.9	3
349	NutriCatt Protocol Improves Body Composition and Clinical Outcomes in Elderly Patients Undergoing Colorectal Surgery in ERAS Program: A Retrospective Cohort Study. Nutrients, 2021, 13, 1781.	4.1	3
350	Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial. Journal of Cancer Research and Clinical Oncology, 2021 , , 1 .	2.5	3
351	Incidence and Predictors of Thrombotic Complications in 4742 Patients with COVID-19 or Other Acute Infectious Respiratory Diseases: A Propensity Score-Matched Study. Journal of Clinical Medicine, 2021, 10, 4973.	2.4	3
352	Principal predictors of major adverse limb events in diabetic peripheral artery disease: A narrative review. Atherosclerosis Plus, 2021, 46, 1-14.	0.7	3
353	Fecal Microbiome Transplantation for Recurrent Clostridioides difficile Infection: Treatment Efficacy, Short and Long-term Follow-up Results from Consecutive Case Series. Journal of Gastrointestinal and Liver Diseases, 2021, 30, 470-476.	0.9	3
354	Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals. World Journal of Hepatology, 2021, 13, 1663-1676.	2.0	3
355	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. Digestive and Liver Disease, 2022, 54, 1215-1221.	0.9	3
356	Factors Associated with ICU Admission in Patients with COVID-19: The GOL2DS Score. Medicina (Lithuania), 2021, 57, 1356.	2.0	3
357	Letter: liver involvement and mortality in COVID $\hat{a}\in \mathbb{R}$ 9 patients $\hat{a}\in \mathbb{R}$ 0 authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 1264-1265.	3.7	3
358	A pilot study of capsule endoscopy after a standard meal for the detection and grading of oesophageal varices in cirrhotic patients. Digestive and Liver Disease, 2014, 46, 997-1000.	0.9	2
359	Watery stools and metabolic acidosis. Internal and Emergency Medicine, 2017, 12, 487-492.	2.0	2
360	Wheat desensitization treatment in patients with gluten sensitivity. Postepy Dermatologii I Alergologii, 2018, 35, 320-322.	0.9	2

#	Article	IF	Citations
361	Going with the gut: probiotics as a novel therapy for hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2019, 8, 295-297.	1.5	2
362	HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?. RMD Open, 2020, 6, e001171.	3.8	2
363	NAFLD or comorbidities, that is the question. Journal of Hepatology, 2020, 73, 723.	3.7	2
364	Quantity of Donor Stool for Fecal Microbiota Transplantation: The More, the Better?. American Journal of Gastroenterology, 2021, 116, 1360-1361.	0.4	2
365	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. Digestive and Liver Disease, 2021, 53, 1603-1609.	0.9	2
366	Recalibrating survival prediction among patients receiving transâ€arterial chemoembolization for hepatocellular carcinoma. Liver Cancer International, 2021, 2, 45-53.	1.3	2
367	May Gender or Ethnicity Affect Delta Over Baseline Values Obtained by 13-C Urea Breath Test?. Reviews on Recent Clinical Trials, 2017, 12, 187-192.	0.8	2
368	Pancytopenia in a Patient with Rendu-Osler-Weber Syndrome and Uncommon Vascular Abnormalities. Case Reports in Hematology, 2016, 2016, 1-2.	0.4	1
369	Olmesartan-associated sprue-like enteropathy: know your enemy. Scandinavian Journal of Gastroenterology, 2016, 51, 891-891.	1.5	1
370	Wire-guided biliary cannulation: a comprehensive approach to a set of techniques. European Journal of Gastroenterology and Hepatology, 2019, 31, 1299-1305.	1.6	1
371	Low seroprevalence of SARS-CoV-2 antibodies in cirrhotic patients. Digestive and Liver Disease, 2021, 53, 541-544.	0.9	1
372	Diet Intervention Study through Telemedicine Assistance for Systemic Nickel Allergy Syndrome Patients during the COVID-19 Pandemic. Nutrients, 2021, 13, 2897.	4.1	1
373	Letter to the Editor: Restructuring the Gut Microbiota of Patients with Cirrhosis After HCV Eradication: A Matter of Time?. Hepatology, 2021, 74, 1718-1718.	7.3	1
374	Diet-Induced Alterations in Gut Microbiota Composition and Function. , 2022, , .		1
375	Development and Validation of Predictive Assessment of Complicated Diverticulitis Score. Journal of Personalized Medicine, 2021, 11, 80.	2.5	1
376	Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach. World Journal of Gastroenterology, 2017, 23, 3195.	3.3	1
377	How to modulate gut microbiota: diet, preprobiotics or antibiotics?. Minerva Gastroenterology, 2017, 63, 411-419.	0.5	1
378	EUS: A one-stop shop approach for pancreatic head masses: Dream or reality?. Endoscopic Ultrasound, 2019, 8, 217.	1.5	1

#	Article	IF	CITATIONS
379	Influence of Antihistamines on Basophil Activation Test in Food Allergy to Milk and Egg. Diagnostics, 2021, 11, 44.	2.6	1
380	Orphan patients with inflammatory bowel disease - when we treat beyond evidence. World Journal of Gastroenterology, 2021, 27, 8047-8057.	3.3	1
381	The Italian National Faecal Microbiota Transplantation Program: a coordinated effort against Clostridioides difficile infection. Annali Dell'Istituto Superiore Di Sanita, 2021, 57, 239-243.	0.4	1
382	Donated stool for faecal microbiota transplantation is not a drug, but guidance and regulation are needed. United European Gastroenterology Journal, 2020, 8, 353-354.	3.8	0
383	Migraine as a Common Extra-Intestinal Presentation of Celiac Disease. , 2021, 5, .		0
384	How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists. Vaccines, 2021, 9, 248.	4.4	0
385	Pasta made with sorghum flour is a valid alternative in the gluten-free diet, reducing metabolic disorders and nutritional deficiencies. Digestive and Liver Disease, 2021, 53, 1527-1528.	0.9	0
386	Bariatric procedures and microbiota: patient selection and outcome prediction. Therapeutic Advances in Gastrointestinal Endoscopy, 2021, 14, 263177452110147.	1.9	0
387	Sarilumab Use in Severe SARS-CoV-2 Pneumonia. SSRN Electronic Journal, 0, , .	0.4	0